U.S. Biodefense Market Size, Share & Trends Analysis Report By Product (Anthrax, Small Pox, Botulism, Radiation/nuclear), And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
U.S. Biodefense Market Growth & Trends
The U.S. biodefense market is anticipated to reach USD 17.90 billion by 2030, and is expected to grow at a CAGR of 4.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. The U.S. biodefense market is driven by factors such as increased government funding, global health concerns, technological advancements, regulatory requirements, the need for collaboration and preparedness, and economic incentives. These drivers contribute to the growth and development of the industry, ensuring that effective biodefense solutions are available to protect populations from potential biological threats. The U.S. biodefense market benefits from rapid advancements in technology, such as genomics, bioinformatics, and synthetic biology. These innovations enable faster identification of pathogens, development of targeted therapies, and improved diagnostics.
In September 2022, the Department of Defense (DoD) planned to invest USD 1 billion to boost domestic bio-industrial manufacturing infrastructure, facilitating accessibility for U.S. innovators, which aimed at incentivizing private and public sectors to expand manufacturing capacities, particularly for critical chemicals vital to commercial and defense supply chains. In addition, the DoD was expected to allocate an extra USD 200 million to enhance biosecurity and cybersecurity measures for these facilities. Collectively, the U.S. Department of Agriculture (USDA) was expected to introduce a USD 500 million grant program in summer 2022 to foster independent, innovative, and sustainable American fertilizer production, leveraging advancements in biotechnology and biomanufacturing to support domestic farmers.
U.S. Biodefense Market Report Highlights
U.S. Biodefense Market Growth & Trends
The U.S. biodefense market is anticipated to reach USD 17.90 billion by 2030, and is expected to grow at a CAGR of 4.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. The U.S. biodefense market is driven by factors such as increased government funding, global health concerns, technological advancements, regulatory requirements, the need for collaboration and preparedness, and economic incentives. These drivers contribute to the growth and development of the industry, ensuring that effective biodefense solutions are available to protect populations from potential biological threats. The U.S. biodefense market benefits from rapid advancements in technology, such as genomics, bioinformatics, and synthetic biology. These innovations enable faster identification of pathogens, development of targeted therapies, and improved diagnostics.
In September 2022, the Department of Defense (DoD) planned to invest USD 1 billion to boost domestic bio-industrial manufacturing infrastructure, facilitating accessibility for U.S. innovators, which aimed at incentivizing private and public sectors to expand manufacturing capacities, particularly for critical chemicals vital to commercial and defense supply chains. In addition, the DoD was expected to allocate an extra USD 200 million to enhance biosecurity and cybersecurity measures for these facilities. Collectively, the U.S. Department of Agriculture (USDA) was expected to introduce a USD 500 million grant program in summer 2022 to foster independent, innovative, and sustainable American fertilizer production, leveraging advancements in biotechnology and biomanufacturing to support domestic farmers.
U.S. Biodefense Market Report Highlights
- Anthrax dominated the product segment with 28.1% share in 2023 owing to its high lethality, ease of production, stability, potential for mass casualties, and the ongoing need to improve existing treatments and vaccines.
- The radiation/nuclear segment is expected to grow at a significant CAGR over the forecast period.
- The increasing incidents of bioterrorism, the potential for new and emerging infectious diseases are contributing to the growth of the U.S. biodefense market.
- In January 2022, Integrated Viral Protection LLC (IVP) launched a portable air filtration device capable of eliminating a wide range of airborne viruses, including COVID-19 and anthrax spores, in a single pass, boasting exceptional efficacy with patented biodefense technology.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.3. Competitive Insights
CHAPTER 3. U.S. BIODEFENSE MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. U.S. Biodefense Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
CHAPTER 4. U.S. BIODEFENSE MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Product Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. U.S. Biodefense Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
4.4.1. Anthrax
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.2. Smallpox
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.3. Botulism
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.4. Radiation/nuclear
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5. Others
4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
CHAPTER 5. COMPETITIVE LANDSCAPE
5.1. Recent Developments & Impact Analysis, By Key Market Participants
5.2. Company/Competition Categorization
5.3. Vendor Landscape
5.3.1. List of key distributors and channel partners
5.3.2. Key customers
5.3.3. Key company heat map analysis, 2023
5.4. Company Profiles
5.4.1. XOMA Corporation
5.4.1.1. Company overview
5.4.1.2. Financial performance
5.4.1.3. Product benchmarking
5.4.1.4. Strategic initiatives
5.4.2. Altimmune, Inc.
5.4.2.1. Company overview
5.4.2.2. Financial performance
5.4.2.3. Product benchmarking
5.4.2.4. Strategic initiatives
5.4.3. EMERGENT
5.4.3.1. Company overview
5.4.3.2. Financial performance
5.4.3.3. Product benchmarking
5.4.3.4. Strategic initiatives
5.4.4. Dynavax Technologies
5.4.4.1. Company overview
5.4.4.2. Financial performance
5.4.4.3. Product benchmarking
5.4.4.4. Strategic initiatives
5.4.5. SIGA Technologies
5.4.5.1. Company overview
5.4.5.2. Financial performance
5.4.5.3. Product benchmarking
5.4.5.4. Strategic initiatives
5.4.6. Elusys Therapeutics, Inc.
5.4.6.1. Company overview
5.4.6.2. Financial performance
5.4.6.3. Product benchmarking
5.4.6.4. Strategic initiatives
5.4.7. Ichor Medical Systems
5.4.7.1. Company overview
5.4.7.2. Financial performance
5.4.7.3. Product benchmarking
5.4.7.4. Strategic initiatives
5.4.8. Dynport Vaccine Company (General Dynamics Information Technology, Inc.)
5.4.8.1. Company overview
5.4.8.2. Financial performance
5.4.8.3. Product benchmarking
5.4.8.4. Strategic initiatives
5.4.9. Cleveland Biolabs
5.4.9.1. Company overview
5.4.9.2. Financial performance
5.4.9.3. Product benchmarking
5.4.9.4. Strategic initiatives
5.4.10. Bavarian Nordic
5.4.10.1. Company overview
5.4.10.2. Financial performance
5.4.10.3. Product benchmarking
5.4.10.4. Strategic initiatives
5.4.11. Ology Bioservices, Inc.
5.4.11.1. Company overview
5.4.11.2. Financial performance
5.4.11.3. Product benchmarking
5.4.11.4. Strategic initiatives
5.4.12. Alnylam Pharmaceuticals, Inc.
5.4.12.1. Company overview
5.4.12.2. Financial performance
5.4.12.3. Product benchmarking
5.4.12.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.3. Competitive Insights
CHAPTER 3. U.S. BIODEFENSE MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. U.S. Biodefense Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
CHAPTER 4. U.S. BIODEFENSE MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Product Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. U.S. Biodefense Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
4.4.1. Anthrax
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.2. Smallpox
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.3. Botulism
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.4. Radiation/nuclear
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5. Others
4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
CHAPTER 5. COMPETITIVE LANDSCAPE
5.1. Recent Developments & Impact Analysis, By Key Market Participants
5.2. Company/Competition Categorization
5.3. Vendor Landscape
5.3.1. List of key distributors and channel partners
5.3.2. Key customers
5.3.3. Key company heat map analysis, 2023
5.4. Company Profiles
5.4.1. XOMA Corporation
5.4.1.1. Company overview
5.4.1.2. Financial performance
5.4.1.3. Product benchmarking
5.4.1.4. Strategic initiatives
5.4.2. Altimmune, Inc.
5.4.2.1. Company overview
5.4.2.2. Financial performance
5.4.2.3. Product benchmarking
5.4.2.4. Strategic initiatives
5.4.3. EMERGENT
5.4.3.1. Company overview
5.4.3.2. Financial performance
5.4.3.3. Product benchmarking
5.4.3.4. Strategic initiatives
5.4.4. Dynavax Technologies
5.4.4.1. Company overview
5.4.4.2. Financial performance
5.4.4.3. Product benchmarking
5.4.4.4. Strategic initiatives
5.4.5. SIGA Technologies
5.4.5.1. Company overview
5.4.5.2. Financial performance
5.4.5.3. Product benchmarking
5.4.5.4. Strategic initiatives
5.4.6. Elusys Therapeutics, Inc.
5.4.6.1. Company overview
5.4.6.2. Financial performance
5.4.6.3. Product benchmarking
5.4.6.4. Strategic initiatives
5.4.7. Ichor Medical Systems
5.4.7.1. Company overview
5.4.7.2. Financial performance
5.4.7.3. Product benchmarking
5.4.7.4. Strategic initiatives
5.4.8. Dynport Vaccine Company (General Dynamics Information Technology, Inc.)
5.4.8.1. Company overview
5.4.8.2. Financial performance
5.4.8.3. Product benchmarking
5.4.8.4. Strategic initiatives
5.4.9. Cleveland Biolabs
5.4.9.1. Company overview
5.4.9.2. Financial performance
5.4.9.3. Product benchmarking
5.4.9.4. Strategic initiatives
5.4.10. Bavarian Nordic
5.4.10.1. Company overview
5.4.10.2. Financial performance
5.4.10.3. Product benchmarking
5.4.10.4. Strategic initiatives
5.4.11. Ology Bioservices, Inc.
5.4.11.1. Company overview
5.4.11.2. Financial performance
5.4.11.3. Product benchmarking
5.4.11.4. Strategic initiatives
5.4.12. Alnylam Pharmaceuticals, Inc.
5.4.12.1. Company overview
5.4.12.2. Financial performance
5.4.12.3. Product benchmarking
5.4.12.4. Strategic initiatives
LIST OF TABLES
Table 1 List of abbreviations
Table 2 U.S. biodefense market, by product, 2018 - 2030 (USD Billion)
Table 1 List of abbreviations
Table 2 U.S. biodefense market, by product, 2018 - 2030 (USD Billion)
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. biodefense market: market outlook
Fig. 9 Biodefense competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 U.S. biodefense market driver impact
Fig. 14 U.S. biodefense market restraint impact
Fig. 15 U.S. biodefense market: Product movement analysis
Fig. 16 U.S. biodefense market: Product outlook and key takeaways
Fig. 17 Anthrax market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 18 Smallpox estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 19 Botulism market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 20 Radiation/nuclear estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 21 Others estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. biodefense market: market outlook
Fig. 9 Biodefense competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 U.S. biodefense market driver impact
Fig. 14 U.S. biodefense market restraint impact
Fig. 15 U.S. biodefense market: Product movement analysis
Fig. 16 U.S. biodefense market: Product outlook and key takeaways
Fig. 17 Anthrax market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 18 Smallpox estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 19 Botulism market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 20 Radiation/nuclear estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 21 Others estimates and forecasts, 2018 - 2030 (USD Billion)
